Course Information

Management of Checkpoint Inhibitor-Related Toxicity

About the Course

Twelve immunotherapy agents have been approved since 2011 in a wide variety of cancers. Immune checkpoint blockade leads to a new spectrum of dysimmune toxicity requiring collaboration between oncologist providers and specialists to improve the understanding of the mechanism, diagnosis, and management of irAEs. The goal of the program is to bring together a multidisciplinary group of clinicians to share expertise and improve the care of patients receiving immune checkpoint inhibitor therapies.

Specialists in dermatology, endocrinology, gastroenterology, oncology, internal medicine, rheumatology/ immunology, nurses, nurse practitioners, physician assistants and residents/ fellows are invited to attend.

Learning Objectives

Following participation in this course the participant will be able to:

  • Describe the mechanism of action associated with checkpoint inhibitor therapies.
  • Identify the spectrum of immune-related adverse events that can occur with immune checkpoint inhibitor therapies.
  • Implement assessment criteria, diagnostic testing, and interventions to improve early identification and management of immune-related AEs.
  • Recognize the importance and necessity of the multidisciplinary approach in treatment of immune-related adverse events.
  • Discuss emerging survivorship issues related to immune-related adverse events.